Aimmune Therapeutics develops treatments to protect people with food allergies from the life-threatening consequences of accidental exposure. The company was founded in 2011 in partnership with Food Allergy Research & Education (FARE), the nation’s leading nonprofit focused on food allergies. AIMT is developing a portfolio of standardized desensitization drug products and protocols for treating food allergy. The company’s lead product, AR-101, is aimed at peanut allergy and was successfully tested in the PALISADE Phase 3 clinical program. In addition to its lead therapeutic candidate, the company also plans to develop products for desensitization to other allergies including egg and walnut.